Today, PATH and Sanofi (Euronext: SAN and NYSE: SNY) announced the delivery of the first large-scale batches of antimalarial treatments manufactured with a new semisynthetic artemisinin derivative to malaria-endemic countries in Africa. The shipment signals a new era of lifesaving drugs made with safe, high-quality, and affordable artemisinin that is non-seasonal. By complementing botanically derived supplies, the new option can widen access to treatment for millions sickened by malaria every year—most of them young children in African countries.
Read PATH’s blog post: “A new era for malaria treatment”
New Antimalarial Treatments Produced with Semisynthetic Artemisinin